Drug Profile
Research programme: JAK1 and JAK2 inhibitors - Incyte Corporation
Alternative Names: INCB 16562; INCB 19408; INCB016562Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Incyte Corporation
- Class Azepines
- Mechanism of Action Janus kinase inhibitors; Janus kinase-2 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cachexia; Essential thrombocythaemia; Myelofibrosis
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Essential-thrombocythaemia in USA (PO)
- 16 Jul 2016 No recent reports of development identified for preclinical development in Myelofibrosis in USA (PO)
- 19 Aug 2012 Pharmacodynamics data from a preclinical trial in Essential thrombocythaemia and Myelofibrosis presented at the 244th American Chemical Society National Meeting (ACS-2012)